Biological E. Ltd.
http://www.biologicale.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biological E. Ltd.
Zydus Looks To Revlimid Opportunity, Pivots To Multivariant COVID-19 Vaccine
Zydus is looking to launch a Revlimid generic in the second wave while an opportunity might soon emerge from Takeda’s Pentasa. It is also pivoting to a multivariant version of its plasmid DNA vaccine against COVID-19, ZyCoV-D, after the original didn’t receive an encouraging response.
Zydus Pivots To Multivariant COVID-19 Vaccine, Looks To Revlimid Opportunity
Zydus is pivoting to a multivariant version of its plasmid DNA vaccine against COVID-19, ZyCoV-D, after the original didn’t receive an encouraging response. It also looks to launch a Revlimid generic in the second wave while an opportunity might soon emerge from Takeda’s Pentasa.
Eight COVID-19 Vaccines Approved In India In 2021, mRNA Addition Awaited
While an mRNA vaccine is still missing, 2021 saw Indian companies strike alliances, battle legal action and gain funding while the regulator played a crucial enabling role in the run up to the approval of eight COVID-19 vaccines from zero in 2020.
Coronavirus Update: AstraZeneca Makes Case For Vaxzevria Booster Against Omicron
Also, AstraZeneca presents more promising data for its COVID-19 antibody cocktail Evusheld and Novavax says its vaccine is able to neutralize the Omicron variant.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- Vaccines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice